ReviewClinical, cosmetic and investigational dermatology2021
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Review in Clinical, cosmetic and investigational dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06278402 (Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Skin cancer risk in alopecia areata: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis.Archives of dermatological research · 2024Pooled it
- Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy: A 60-Week Observational Study.Dermatology and therapy · 2026Article
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Association of Janus kinase inhibitors with reduced depression in alopecia areata.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases.ACR open rheumatology · 2025Review
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia AreataBalkan medical journal · 2025Article
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.Cureus · 2025Review
- Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia.Life (Basel, Switzerland) · 2024Review
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database.The Journal of dermatology · 2024Article
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment.The Journal of dermatology · 2024Article
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician's Survey in the Middle East.Dermatology and therapy · 2023Article
- Baricitinib: A Review in Severe Alopecia Areata.American journal of clinical dermatology · 2023Review
- Impact and Management of Loss of Eyebrows and Eyelashes.Dermatology and therapy · 2023Review
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata.Skin health and disease · 2023Article
- Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.Journal of the American Academy of Dermatology · 2023Article
- Article
- Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective.Journal of managed care & specialty pharmacy · 2023Article
- Recent advances in the genetics of alopecia areata.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is a chronic, immune-mediated form of nonscarring alopecia that is multifactorial and results in localized patches. It is often described as a self-limiting condition that results in the spontaneous regrowth of hair in most cases. However, this regrowth may take several months or years to occur in some patients, leading to the development of psychoemotional trauma in those that are affected. Although several therapies for AA have been developed and tested, there is no specific treatment that has been approved, leading to the availability of many off-label conventional treatment options, with very limited responses. More recently, with the advancement of pre-clinical and genetic studies, a greater understanding of the pathomechanisms involved in the development of AA has been uncovered. This has resulted in the introduction of targeted therapies that use small molecules to block specific pathways involved in AA pathophysiology. As such, the use of janus kinase (JAK) inhibitors for treatment of AA has emerged. JAK inhibitors block the T-cell mediated inflammatory response thought to be the driving factor behind AA pathogenesis, by inhibiting the janus kinase (JAK) signal transducer and activator of transcription (STAT) signaling pathway, leading to a reversal of hair loss in AA patients. Thus, in an effort to demonstrate the efficacy of JAK inhibitors in the treatment of AA, several studies have been published within recent years. However, the question remains, "Are JAK inhibitors effective and safe in the management of Alopecia Areata?". This review aims to provide a comprehensive report on the role, efficacy, and outcomes of using JAK inhibitors in the treatment of AA. To competently answer the research question highlighted, the most recent, quality articles published over a 10-15-year period were sourced using PubMed, NCBI, Research gate, Medline, Cochrane Central Register of Controlled Trials, EMBASE and Google scholar. The literature search was primarily focused on randomized controlled trials (RCTs); however, in the absence of such, only the most recently published case reports, case series, clinical trials and open-label studies published to date were included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.